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Wilms tumour (WT) is the most common paediatric kidney cancer and affects approximately one in 10 000 children.
The tumour is associated with undifferentiated embryonic lesions called nephrogenic rests (NRs) or, when diffuse,
nephroblastomatosis. WT or NRs can occur in both kidneys, termed bilateral disease, found in only 5–8% of cases.
Management of bilateral WT presents a major clinical challenge in terms of maximising survival, preserving renal
function and understanding underlying genetic risk. In this review, we compile clinical data from 545 published
cases of bilateral WT and discuss recent progress in understanding the molecular basis of bilateral WT and its
associated precursor NRs in the context of the latest radiological, surgical and epidemiological features.
Introduction
Wilms tumour (WT) is a rare kidney cancer that occurs
almost exclusively in childhood, with a prevalence of
one in 10 000 children younger than 15 years of age.
This embryonal tumour generally shows mimicry of
cell types seen during normal nephrogenesis, with the
classical ‘triphasic’ WT comprising undifferentiated
blastemal cells with differentiation towards both
stromal and epithelial elements. The genetics of the
embryonal tumours of childhood underpinned
Knudson’s two-hit hypothesis for cancer generation
whereby a tumour suppressor gene is silenced by
either germline or random somatic loss-of-function
mutation of one allele, with the remaining allele lost
as a second event post-natally. Hereditary cases are pre-
dicted to occur earlier and be more likely to present
bilaterally in paired organs such as the kidney.
However, when the first WT gene (WT1) was identi-
fied, it was found to account for only a minority of
bilateral and familial WT cases. Indeed, genetic predis-
position to WT is uncommon (∼5% of all cases) and
can be owing to one of several different genetic or epi-
genetic changes (Ref. 1, 2). With the recent discovery
of many new WT genes, the proportion with known
genetic predisposition may increase, especially if
some have low penetrance (Refs 3, 4, 5).
WTs presenting as bilateral disease can be associated
with early disruption in renal development, not only
because of involvement of both kidneys but due to
the fact that in nearly all cases, tumours are associated
with the presence of precursor lesions termed nephro-
genic rests (NRs). NRs are clusters of residual
embryonic renal cells persisting in a mature kidney
that result from incomplete differentiation of metaneph-
ric blastema into mature renal parenchyma (Refs 6, 7).
Two types of NR are recognised based on morpho-
logical features and anatomical location within
the kidney. Intralobar NR (ILNR) are usually observed
singularly and show predominant stromal composi-
tion and often mature fat cells with irregular, indis-
tinct borders and are located towards the renal
medulla whereas perilobar NR (PLNR) are often
numerous and diffuse located towards the periphery
of the renal lobule composed predominantly of blaste-
mal cells with well-defined borders that develop epithe-
lial structures and sclerosis with age (Refs 6, 7).
Nephroblastomatosis is defined as the presence of mul-
tiple or diffuse NR. In unilateral WTs, NRs are usually
only detectable by histology whereas in bilateral WT,
the proliferating NRs may be large enough to be seen
on imaging (Ref. 8). The term ‘bilateral disease’ is
used to encompass bilateral WT, WT in one kidney
with nephroblastomatosis in the other, or bilateral
nephroblastomatosis, as these cannot always be easily
distinguished on imaging. Whilst NRs are considered
benign and can regress spontaneously or under chemo-
therapy, they have a significant risk of progression to
WT (Ref. 9).
Bilateral disease can be synchronous (both kidneys
affected at the same time) or metachronous (one
affected after the other), which occurs in 6.3 and
0.85% WT patients respectively (Ref. 10) with an
overall frequency of ∼5 to 8% (Refs 11, 12). In
general, PLNRs are associated with synchronous
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bilateral WT, whereas ILNRs are more strongly asso-
ciated with metachronous WT (Ref. 6). As expected
from Knudson’s two-hit model, the median age of
onset of bilateral WT is younger than for unilateral
WT – under 2 years compared with 38 months. What
remains unexplained is the remarkable female excess
seen in bilateral WT (Ref. 12). Furthermore, the
bimodal distribution of age at onset implies a genetic
complexity that is as yet only partially understood.
For both unilateral and bilateral WT, age at diagnosis
is affected by the presence of NRs, patient sex (males
are diagnosed on average 6 months earlier than
females), underlying syndromes and laterality
(Refs 6, 10).
At present, bilateral disease is treated with pre-
operative chemotherapy at time of diagnosis followed
by surgery. A major clinical challenge is to decide
the best time for nephron-sparing surgery (NSS) and
if and when there may be value in intensifying
or prolonging pre-operative chemotherapy. Thus far,
response assessment is based purely on tumour shrink-
age. However, it is recognised that the stromal subtype
of WT, common in children withWT1mutant tumours,
may not shrink and may even show a paradoxical
increase in tumour size owing to rhabdomyoblastic dif-
ferentiation, even though it is a favourable histological
subtype. Hence, having a technique that could monitor
histological response during pre-operative chemother-
apy would be useful in planning NSS. Advanced func-
tional imaging using apparent diffusion coefficient
(ADC) is a new approach that has the potential to
make this distinction (Ref. 13). Furthermore, while
WT needs to be surgically removed (Ref. 14), NRs
may be left within a patient in some circumstances
making their distinction from WTs essential for effect-
ive treatment. Patients with bilateral disease need to
maintain maximal renal function to ensure longevity
requiring advanced imaging and surgical techniques.
Here, we review the most recent advances in these
fields and explore the molecular biology aspects of
bilateral WT.
Search strategy and selection criteria
References for this Review were identified through
searches of PubMed, using appropriate search terms
for each section, for the period from 1990 until August
2016 (‘Nephroblastoma’ or ‘Wilms’, ‘Bilateral’ and
‘Nephroblastomatosis’). For the surgical section, only
reviews by national or cooperative groupswere included
because of a recent comprehensive review of this
aspect published in 2009 (Ref. 15). Only papers pub-
lished in English were reviewed. The final reference
list was generated on the basis of originality and rele-
vance to the broad scope of this Review.
WT predisposition syndromes
Unlike adult carcinomas where cells have a lifetime to
accumulate damage, the embryonic tumours of child-
hood are felt to represent random spontaneous genetic
changes in a pool of cells that retain the pluripotent dif-
ferentiation potential of their embryonic counterparts.
However, in certain cases, a germline mutation predis-
poses to WT onset by either providing the first tumour
suppressor gene ‘hit’, as previously discussed, or by
causing sustained proliferation of renal precursors pro-
viding an optimal environment for a second transform-
ing event. Not surprisingly, a much higher frequency of
bilateral disease is observed in patients with predispos-
ition syndromes.
Approximately 5% of WTs are associated with
known constitutional predisposition syndromes; whilst
over 100 syndromic associations are described (Ref. 1),
the commoner ones fall into two major categories:
those associated with genito-urinary malformation
because of underlying abnormalities in the WT1 gene
(WT with Aniridia, Genitourinary abnormalities and
mental Retardation (WAGR) syndrome; Denys–Drash
syndrome (DDS)) and those associated with an over-
growth phenotype [Beckwith–Wiedemann syndrome
(BWS) and Perlman syndrome].
WAGR syndrome is associated with 11p13 deletion
encompassing the WT1 gene. The size of the deletion
varies, with mental retardation observed in patients
with large deletions. Subsequent to germline WT1
loss, the second somatic event leading to WT formation
in patients with WAGR syndrome is commonly intra-
genic WT1 mutation, rather than a second 11p
genomic loss, as the latter is likely to be cell lethal.
Of children born with WAGR syndrome, 45–57%
develop WT (Refs 16, 17). A range of germline intra-
genic WT1 mutations have been associated with DDS
with the majority affecting the WT1 DNA-binding
domain, specifically within exon 9 (Ref. 18).
Although the penetrance of WT in children with consti-
tutional WT1 mutation is likely much lower, around
74% children with the classical DDS triad develop
WT, often with associated ILNRs (Ref. 18) (using the
original narrow phenotypic definition of DDS and
not including the more recently broadened phenotype
with milder renal dysfunction/genitourinary abnormal-
ities with WT1 mutation).
Germline aberration of WT1 is clearly associated
with increase in bilateral disease as the overall rate of
bilateral WT is 5% whereas patients with DDS show
incidence of 20% (Ref. 18), and WAGR 17%
(Ref. 19). A similarly high frequency (17.3%) of bilat-
eral disease is observed in patients with BWS (Ref. 20),
who show germline loss of imprinting (LOI) at 11p15,
affecting IGF2 and H19 either by gain of DNA methy-
lation or uniparental isodisomy giving two copies of
the active paternal IGF2 allele. However, penetrance
is much lower for BWS patients, as only 7.5%
develop WT (Ref. 20), often associated with PLNRs.
Perlman syndrome is similar to BWS in that both syn-
dromes cause overgrowth, however, the greatest overall
frequency of bilateral disease is observed in association
with Perlman syndrome. Of the children who survive
the prenatal period, 64% develop WT and 55% of
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these are bilateral. Perlman syndrome is associated with
DIS3L2mutation and frequently observed with nephro-
blastomatosis. Other germline genetic anomalies have
been associated with bilateral WT, including duplica-
tion of 2p24.3 encompassing genes DDX1 and
MYCN (Ref. 21), de novo t(5;6)(q21;q21) affecting
HACE1 (Ref. 22) and mosaic variegated aneuploidy
(Refs 23, 24).
None of these predisposing syndromes show 100%
association with bilateral disease, as there is a require-
ment for a second event prior to tumour formation. The
frequency of bilateral disease may be associated with
the developmental timing at which the primary aberra-
tion occurs. For patients with Perlman syndrome, a very
high number develop WT in one or both kidneys
whereas for BWS this is much lower suggesting that,
on a background of germline DIS3L2mutation, a trans-
forming second event occurs more readily, whereas on
a background of IGF2 overexpression and H19 loss,
there is less selection pressure for transformation.
Another potential confounder is the presence of mosai-
cism in patients, where certain tissues may carry the
aberration and others not, and even certain cells
within the tissue, if the aberration occurs late in
development.
Molecular features of bilateral WT (Fig. 1)
WT1 and bilateral WT. WT1 mutation is observed in
∼12% sporadic WTs (Ref. 25) and germline WT1
mutation or loss significantly increases the likelihood
of developing bilateral disease. In a comprehensive
review of 117 published WT cases with germline
WT1 alterations, the authors showed a frequency of
bilateral WT in 24, 17 and 52% of the deletion, mis-
sense and truncation mutations groups (Ref. 26).
When the truncation group was subdivided further,
the frequency of bilateral WT was 50% for patients
with frameshift and 54% for patients with nonsense
mutations (Ref. 26). Two studies that performed WT1
analysis in large cohorts of nonsyndromic patients
with WT found that 8/201 (4%) (Ref. 27) and 6/282
(2%) (Ref. 28) patients had constitutional WT1 muta-
tion with three and two of these having bilateral
disease, respectively. This shows that a relatively low
frequency of cases thought to be sporadic may in fact
be germline, despite the patients showing no other
obvious clinical phenotype.
Taking the opposite approach, another study focused
specifically on assessment of germline WT1 status in
patients with bilateral disease. By targeted sequencing
of WT1 in eight bilateral WTs (defined in this case as
only synchronous bilateral tumours), three patients
were found to have germline heterozygous nonsense
mutations in WT1 exon 8, leading to WT1 protein trun-
cation with no wild-type allele present in the tumours
(Ref. 29). The other five patients had noWT1 mutation
and were not further characterised for germline or
somatic mutation of other WT genes. A separate
study described a much higher frequency, with seven
of eight patients with bilateral disease (defined here
as either WT in each kidney or WT with NR in the
other kidney) showing germline WT1 mutation
(Ref. 30). The final patient had BWS and no WT1
mutation (Ref. 30). Of the seven WT1 germline
mutant cases, three patients relapsed; all of whom ini-
tially had WT and one NR in the contralateral kidney.
Two patients developed WT in the kidney with previ-
ous NR and one patient developed bilateral WTs. As
one of these recurrences was 11 years later, the
authors suggest careful follow up for patients with
bilateral disease. Although no molecular analysis was
performed on the recurrences, the authors did look
for CTNNB1 mutation in the tumours and NRs. It has
been hypothesised that WT1 mutation is an initiating
event and CTNNB1 mutation a secondary event in
WT tumourigenesis as WT1 mutations have been iden-
tified in both NRs and WTs, but CTNNB1 mutations
only in the associated WTs (Ref. 31). However, the
data shown in this study did not agree with this
model, because for the three cases where both the
WT and contralateral NR were examined for
CTNNB1, two showed both the NR and WT were posi-
tive for CTNNB1 mutation while the last case was
uninformative.
In a separate study where CTNNB1 mutations were
specifically studied in a patient with germline WT1
mutation and bilateral WTs, both tumours had a
second WT1 hit of loss of heterozygosity (LOH),
while the right tumour had delta45S CTNNB1mutation
and the left side had S45P in all cell types and a T41A
CTNNB1 mutation specific to a separately microdis-
sected stromal component (Ref. 32). The surrounding
kidney was shown to be absent for CTNNB1 mutation
or LOH. These data support CTNNB1mutation being a
later event in WT tumourigenesis, which is further sup-
ported by the fact that new bilateral WTs subsequently
developed with novel CTNNB1mutations (S45C on the
right; S45F on the left) (Ref. 32). A separate study that
showed three of five tumours within one patient had
different CTNNB1 mutations (delta45, S45C and
S45P) (Ref. 33).
Although the evidence for CTNNB1 mutation being
a late event is inconsistent, these studies, and others
(Refs 34, 35) clearly demonstrate that WT1 mutation
can follow the 2-hit tumour suppressor model for
the development of cancer. However, the somatic
genetics can be complex, with WT1 mutant proteins
demonstrating tumour suppressor functions in some
cases and oncogenic properties in others. The differ-
ing roles for WT1 are further supported by the differ-
ence in clinical phenotype observed in patients with
WT1 loss and WT1 mutation; a dominant-negative
effect is predicted for intragenic WT1 point mutations
because of the more severe genitourinary phenotype
observed in patients with DDS in comparison with
patients with complete WT1 deletion (WAGR
syndrome).
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IGF2 and bilateral WT. In healthy normal tissue, the
expression of IGF2 (located at 11p15) is controlled
by a nearby imprinting control centre, at which the
DNA is methylated on the paternal allele and not
methylated on the maternal allele. Expression of
IGF2 occurs only when the imprinting control centre
is methylated, i.e. from the paternal allele. This
normal phenomenon, termed ‘genomic imprinting’ is
disrupted in WTs. Somatic biallelic expression
because of the loss of the silent maternal allele and
duplication of the active paternal allele by LOH is
observed in 32% and LOI by gain of methylation is
observed in 37% WTs, with overall frequency of
around 70% (Ref. 25), reviewed elsewhere (Ref. 36).
The low frequency of tumours observed in patients
with constitutional LOI may be explained by the pres-
ence of mosaicism. 11p15 aberration in lymphocyte
DNA has been described in 12% of patients with bilat-
eral WTs and 3% of unilateral sporadic WTs without
reported syndromes or associated overgrowth
(Ref. 2). Furthermore, mosaic LOI has been reported
in the kidney in patients without constitutional aberra-
tion (Ref. 37). Therefore, the reverse may be true; that
patients with ‘germline’ LOI may show LOI in many
tissues, but not the kidney, hence the absence of
tumour formation.
In addition to the strong association between consti-
tutional LOI at 11p15 and an increased frequency of
bilateral WT, bilateral disease was also significantly
more frequent in sporadic WTs with somatic LOI by
gain of methylation, compared with tumours without
(P< 0.001) (Ref. 25) and LOI by LOH was shown to
occur infrequently in bilateral tumours compared with
unilateral (Ref. 38). Therefore, despite a relatively
low penetrance level, LOI by gain of methylation at
11p15 is clearly associated with both unilateral and
bilateral WTs, indicating a disruption in normal epigen-
etic control.
Recently discovered WT genes. Besides WT1 and IGF2,
several other genes or chromosomes have been ana-
lysed in bilateral WTs. Whether these are causative
for the predisposition or for the individual tumour ana-
lysed remains unanswered and addressing the latter
requires detailed analysis of multiple tissue samples
from one individual, which is not always achieved in
the small series or anecdotal series described. One
study highlighted a specific case of bilateral WT in
which isochromosome 7q was observed only in the
left tumour (Ref. 39). Anaplastic histology, associated
with TP53 mutation, is also frequently discordant
between bilateral tumours and hence is believed to be
a later event in tumourigenesis (Ref. 40). An example
is the longitudinal analysis of a patient with bilateral
disease, where TP53mutation was not initially detected
at diagnosis in biopsies of either side but was found 5
ILNR BWT
MET
PLNR BWT
PLNR/ILNR
DIS3L2 mutation
BWT
(+ CTNNB1mut)
TP53 loss
CTNNB1 mut
Large copy number changes
MYCN gain
prolif.
Nephroblastomatosis
Late events
Embryonic development
2p24.3 dup
t(5;6)(q21;q21)
none/other aberration
WT! mut/del
11p15 LOI
Bilateral Wilms tumour (BWT) is frequently associated with germline genetic or
epigenetic aberrations.
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FIGURE 1.
Bilateral Wilms tumour (BWT) is frequently associated with germline genetic or epigenetic aberrations. During kidney development, kidney
precursor cells undergo mesenchymal to epithelial transition (MET) to form the epithelial structures of the normal kidney (light orange). In
cases where cells carry germline aberrations (but not in every case), normal development is disrupted and retained embryonic tissue is
found in the normal kidney (nephrogenic rests; dark orange). Intralobar nephrogenic rests (ILNR) are associated with WT1 mutation and peri-
lobar nephrogenic rests (PLNR) are associated with 11p15 loss of imprinting (LOI). These lesions are considered precursors to Wilms tumour
and are found in nearly all cases of bilateral Wilms tumour (BWT; dark red) although the molecular mechanisms involved in transformation are
unknown. Mutation of CTNNB1 is likely to be a secondary event following germline WT1 mutation. Further late events are acquired over the
progression of the tumour. Shown in black are several reported germline aberrations found in patients with BWT, however the genetic back-
ground is not always known and BWT could also arise from somatic mutation in each kidney.
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months later in the left kidney tumour (p173V> L),
with a different mutation (p195I> T) being found at
subsequent relapse 56 months later in the contralateral
kidney, where a residual right-sided NR had trans-
formed to WT (Ref. 41). A more recent study analysed
MYCN and TP53 status in a pair of bilateral WTs and
identified TP53 mutation and MYCN copy number
gain in the left tumour with wild-type TP53 and activat-
ing MYCN mutation in the right tumour (Ref. 42).
When the right kidney suffered a later recurrence, a dif-
ferent TP53 mutation and wild-type MYCN were
found, suggesting this was a new tumour rather than
relapse of the original. As the relapse was MYCN
wild-type, gain of MYCN was clearly not required for
tumour formation; however, it is interesting that both
tumours contained activated MYCN, albeit by alterna-
tive mechanisms. These findings suggest that although
MYCN gain and TP53 loss are late events in Wilms
tumourigenesis, both molecular aberrations can
promote tumourigenesis.
Evidence frommouse models also highlights genetic
events that may lead to bilateral disease including the
combination of CTNNB1 mutation with KRAS activa-
tion in which mice developed bilateral WT-like renal
epithelial tumours that were metastatic and multifocal
(Ref. 43). However, KRAS has not been identified as
a human WT-associated gene. On the other hand,
Lin28a overexpression, led to mainly bilateral
tumours (4/5 tumours observed in 50 mice) when it
was serendipitously overexpressed from ‘leaky’ expres-
sion in a primordial germ cell lineage mouse model
experiment (Ref. 44). A further mouse model inducing
spatial and temporal control of Lin28a expression in
mouse yielded 15 tumours in 15 mice; however, the fre-
quency of bilateral lesions was not discussed. Lin28a
human homologue LIN28B, was also shown to be over-
expressed in the blastemal component of human WT
(Ref. 44). LIN28 overexpression is associated with
degradation of Let-7 miRNAs, and as Perlman syn-
drome is associated with DIS3L2 mutation, the nucle-
ase that degrades poly-uridylated let-7 miRNAs
(Ref. 45), and also shows high rates of bilateral WT,
this indicates that the miRNA processing pathway
may be particularly penetrant for generating bilateral
WTs.
More recently, additional genes were found to be
mutated in WT, including genes involved in early
renal development (SIX1, SIX2 and SALL2) as well
as genes involved in the miRNA processing pathway
(DIS3L2, DGCR8, DICER1, DROSHA, XPO5 and
TARBP2) (Refs 4, 5, 46, 47). It is currently unclear
whether there is a link between these novel gene muta-
tions and bilateral disease however mutations in several
(DICER1, DROSHA, DGCR8, XPO5 and DIS3L2)
have been observed in the germline (Refs 4, 5, 47, 48).
Finally, a very recent article showed intra tumour
genetic heterogeneity in WT, bilateral WT appearing
genetically distinct and probably arising independently
one side from the other (Ref. 49). Such variable
heterogeneity will probably become predominant in
the near future research to better understand the real
genetic landscape of syndromic and nonsyndromic
bilateral WT. It may have major implications in the
clinical decision-making process to more accurately
adapt and personalise treatment strategies for each indi-
vidual cases.
Molecular features of NRs and its clinical
consequences
By contrast to WT, genetic and molecular studies of
NR are scarce because of the difficulty of distinguish-
ing NR from WT and specifically extracting suitable
DNA from small microscopic lesions (Ref. 50). WT1
mutation was identified in the NR of 2/19 patients
with WT (Ref. 51) and loss of 11p13 and 11p15 hetero-
zygosity were found in the ILNR of 2/12 patients
(Ref. 52). PLNRs also appeared to be associated with
IGF2 overexpression and WT in 42 patients but these
PLNRs displayed various genomic profiles suggesting
that not all PLNR necessarily underwent malignant
transformation (Ref. 53). Epigenetic research has
recently shown intermediate levels of DNA methyla-
tion in NR compared with WT, these methylated
regions becoming further methylated with the develop-
ment of an associated WT (Refs 54, 56). To our knowl-
edge, no molecular analysis of bilateral NRs has been
reported so far. In the largest study of patients with
diffuse nephroblastomatosis visible on imaging, no
molecular analyses were described (Ref. 9).
Thus, differentiating WT from its associated and pre-
sumed precursor NR remains challenging on a molecu-
lar basis. It would be of great value clinically if imaging
features could also contribute to the assessment of this
distinction, to predict histological risk group and hence
aid with surgical planning of NSS.
Clinical features
Despite the lack of controlled studies, reports from
recently published cooperative, national groups or
single institutional series from developing countries
with at least 15 patients provide useful data allowing
identification of some key features specific to bilateral
WT (Refs 20, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65).
Clinical characteristics are detailed in Table 1. Age of
onset of bilateral WT varied from 15 months to 3.6
years, the lowest being the Japanese series that also pre-
sented with the highest rate of associated anomalies,
while the highest age of onset was observed in patients
from Cape Town that had no associated anomalies
(Refs 61, 62). We could argue that better screening of
patients followed by paediatricians for other anomalies
allows an earlier detection of an abdominal mass. A
total of 120 (22%) patients among the 545 listed had
associated syndromes or clinically relevant anomalies,
the commonest being isolated genito-urinary anomalies
(35%), i.e. hypospadias or undescended testis, that
were not associated with an already described syn-
drome. The second most frequent anomaly was isolated
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TABLE 1.
CLINICAL FEATURES OF BILATERAL WT
AEIOP (Ref. 59) SFCE
(Ref. 64)
NWTS (Ref. 58) JPLT (Ref. 62) GPOH/SIOP9
(Ref. 65)
UKW2
(Ref. 60)
Netherlands
(Ref. 56)
Egypt
(Ref. 63)
Durban (Ref. 57) Cape Town
(Ref. 61)
Total
Number of
patients
93 49 188 31 28 70 25 22 20 19 545
Date of study 1990–2011 1993–2001 1986–1994 1996–2011 1989–1994 1980–1995 1967–2007 1993–2008 2002–2012 1981–2003 1967–2012
Median or
mean age
24 m [5–86] 2.3 y [1.7 m-
8.4y]
32 m [1–127] 15 m [7–62] 1.9 y 24.4 m
[1–102]
1.03 y
[0.27–5.35]
3y [1–9] 2.5y [10 m-9y] 3.6 y
[0.6–7.9]
Sex 32 M
61 F
18 M
31 F
74 M
114 F
16 M
15 F
28 M
42 F
7 M
18 F
10 M
12 F
11 M
9 F
7 M
12 F
203 M
314 F
BWS 3 0 10 0 2 2 0 0 17
DD 1 4 0 2 with WT1
mutation
3 3 1 0 14
WAGR 2 3 1 0 5 0 0 0 11
Isolated
aniridia
2 1 6 0 At least one with
11p13
deletion
0 0 0 0 7
Isolated HH 5 1 15 0 0 0 1 0 22
Perlman 1 1 0 0 2 0 0 0 4
GU
anomalies
0 1 6 hypospadias
11 undescended
testis
3 hypospadias
4 undescended
testis
1 horseshoe
kidney
15 0 1 hypospadias with
undescended
testis
0 42
Other 1 Prune Belly
1 Mental and
growth retardation
0 0 1 familial WT 0 0 0 0 3
WT1
mutation
21 (68%) 21
S or Me All S All S All S All S All S All S 14 S
11 Me
19 S
3 Me
14 S
5 Me
506 S
19 Me
Metastatic 11 (12%) 5 (10%) 16 (8.5%) 2 (6%) 3 (11%) 9 (13%) 2 (8%) 0 4 (20%) 1 (5%) 53 (9.7%)
M, male; F, female; m, months; y, years; BWS, Beckwith–Wiedemann Syndrome; DD, Denis-Drash; WAGR, Wilms, Aniridia, Genito-urinary malformations and mental Retardation; HH, hemi-hypertrophy;
GU, genito-urinary; S, synchronous; Me, metachronous. BIL
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hemi-hypertrophy observed in 22 (18.3%) patients. The
three syndromes associated with different 11p abnor-
malities (WAGR, DDS and BWS) were equally repre-
sented, ranging from 2 to 3% of the whole cohort and
from 9.1 to 14.1% of the patients with clinical anomal-
ies. Conversely, bilateral WT has been reported in
17.3% of BWS patients (Ref. 20), which was three
times higher than in the whole WT population, but
similar to the rate reported in DDS and WAGR
(Refs 18, 19, 20). Hemihypertrophy and nephromegaly
have been reported as major risk factors of developing a
WT, nephromegaly being particularly linked with bilat-
eral cases (Ref. 66). Molecular features of an unse-
lected series of bilateral WT have only been reported
by the Japanese national WT group, who found a
high proportion (68%) with WT1 mutation (Ref. 62).
It should be noted however that the Japanese popula-
tion has a much lower proportion of WT associated
LOI at 11p15 than is found in populations of largely
Caucasian descent (Ref. 67). No further data on the
clinical, radiological, pathological and treatment differ-
ences between patients with or without syndromic pat-
terns were displayed in these national series.
The only national series reporting on bilateral
disease associated with nephroblastomatosis presented
52 patients with hyperplastic perilobar nephroblasto-
matosis, including three patients with unilateral
lesions and 49 with bilateral lesions. Among them,
24 developed a WT in their follow-up; 13 a single
WT and 11 developed two or more synchronous or
metachronous uni or bilateral WTs. The histology of
the nephrectomy showed a higher percentage of ana-
plastic WT (33% of those who developed a WT, 15%
of the whole cohort) (Ref. 9). Distinguishing nephro-
blastomatosis from WT at diagnosis is one of the
most difficult aspects of bilateral disease and has clin-
ical significance as the overall prognosis of having a
WT associated with nephroblastomatosis led to worse
overall and event free survival compared to having an
isolated WT (Ref. 68). The study of multiple nephro-
blastomatosis cases described here showed that the
initial biopsy did not aid with distinction in 63% of
cases (Ref. 9). Instead, the most reliable pathologic
feature seemed to be the presence of a well-defined
fibrous pseudo-capsule separating the lesion from the
adjacent normal kidney in WT (Ref. 9).
Radiological features
Bilateral WTs are usually associated with NRs that are
small, microscopic lesions not visible on imaging.
However, some cases present with one or more expan-
sile lesions seen on imaging. The smallest lesion
detectable by ultrasound is at least 8 and 5 mm by
CT scan or MRI (Ref. 69). Distinguishing NR from
WT is difficult, the most characteristic feature of NR
at diagnosis being their diffuse homogeneity both
before and after contrast agent administration. After
chemotherapy, MRI has been shown to differentiate
the active NR and WT (bright on T2 and STIR
sequences) from inactive NR and treated WT (dark
on T2-weighted images and STIR sequences). The
shape of the lesion may aid distinction because of the
more oblong or lenticular shape of NRs; however,
they can also be spherical like WT, resulting in less
than perfect specificity and sensitivity of MRI and
CT in the distinction between WT, NR and nephroblas-
tomatosis (Ref. 70).
Nephroblastomatosis in its diffuse hyperplastic peri-
lobar form is confined to the periphery of the kidneys.
Its appearance is usually hypointense to the cortex and
isointense to the medulla in MRI nonenhanced T1-
weighted images, and hyperintense on T2-weighted
images with similar appearance of the cortex.
Contrast enhanced MRI or CT make the lesions the
most conspicuous (Fig. 2) (Ref. 9).
The recent development of diffusion-weighted MRI
in paediatric abdominal tumours (Ref. 71) has shown
an inverse relationship between the cellularity of extra
cranial tumours and the ADC of these tumours
(Ref. 72). The use of ADC measurements to enable dif-
ferentiation between benign and malignant tumours
shows controversial results, potentially explained by a
difference in the drawing of the region of interest that
should not include any necrotic or cystic area as these
areas render ineffective ADC measurement (Refs 71,
72). So far, in WTs, diffusion-weighted MRI has
been able to stratify WT histological subtypes with sig-
nificantly lower values observed in high-risk blastemal-
type WTs compared with intermediate risk stromal,
regressive and mixed-type. No significant difference
in ADC was found between blastemal-type WTs and
intermediate risk epithelial-type (Ref. 13). This may
be particularly important for identifying the proportion
of blastema that has responded to chemotherapy, and
the proportion of residual chemotherapy-resistant blas-
tema, as mentioned in the introduction. Ongoing
studies are assessing the prognostic significance of
these measurements.
Treatment for bilateral disease
The preoperative chemotherapy regimen favoured
when primary surgery was not performed was a
course of Vincristine and Actinomycin D, with or
without Doxorubicin for a mean duration of about 3
months before the first surgery (Table 2). The timing
of performing Nephron NSS or radical nephrectomy
reached a consensus on the need to operate before the
12th week of preoperative chemotherapy, first
because of the risk of anaplastic transformation
(Ref. 73), then because continuing chemotherapy
longer will not facilitate conservative resection
(Ref. 65) and because nonresponding tumours on
radiological assessment may be differentiated
tumours (like stromal type) that will not shrink more
under further chemotherapy. NSS was performed in
344/517 (66%) patients, combining radical nephrec-
tomy on one side and NSS on the other side (n=
192), bilateral NSS (n= 127), unilateral NSS and
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biopsy on the other side (n= 11) or unilateral NSS
alone (n= 14) (Table 3). Twenty-two additional NSS
were performed by the Durban surgical team but with
no detail on the side of the surgery (Ref. 57). For
central tumours involving the renal hilus, a longitudinal
partial nephrectomy was reported in five bilateral WT
patients, three of them carrying a WT1 mutation, with
good oncological and outcome results (Ref. 74).
The quality of resection could be evaluated by the
number of surgical complications and the number of
stage III. Surgical complications occurred in 40/517
(7.7%) patients leading to death in two Italian patients
(one chylous ascites and one acute cerebral ischaemia)
(Ref. 59) (Table 3). These surgical fatal complications
led the Italian group to advocate for a more centralised
management of bilateral WT, also noticing that the
highest rate of conservative procedures arose from a
single expert institution (Ref. 59).
The final pathological analysis showed about 30%
WTs were stage III in major series (Refs 58, 59, 64,
65) but without distinguishing radical nephrectomy
from NSS. Reasons for stage III were not detailed,
but one could argue positive margins as well as omis-
sion of lymph nodes sampling that seems more
Expert Reviews in Molecular Medicine © 2017 Cambridge University Press
MRI images of bilateral nephroblastomatosis enhancing the diffuse
homogeneity and the rind-like peripheral location of the lesions a
compared to the heterogeneity and round shape of bilateral WT b.
a b
c d
FIGURE 2.
MRI images of bilateral nephroblastomatosis enhancing the diffuse homogeneity and the rind-like peripheral location of the lesions (a) com-
pared with the heterogeneity and round shape of bilateral WT (b). The left kidney seems suitable to a nephron sparing surgery as the mass arises
from the superior pole above the left pedicle (b). Corresponding apparent diffusion coefficient (ADC) maps demonstrate low ADC in both
kidneys with nephroblastomatosis (c) but different ADC values between the right solid nephroblastoma and the left cystic tumour (d).
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TABLE 2.
TREATMENT MODALITIES AND OUTCOME OF BILATERAL WT PATIENTS
AEIOP (Ref. 59) SFCE (Ref. 64) NWTS
(Ref. 58)
JPLT (Ref. 62) GPOH/
SIOP9
(Ref. 65)
UKW2
(Ref. 60)
Netherlands
(Ref. 56)
Egypt (Ref. 63) Durban
(Ref. 57)
Cape Town
(Ref. 61)
Number of
patients/kidneys
93/176 49/94 188/376 31/56 28/ 70/114 25/ 22/ 20/37 19/
Preop CT 43 VA
37 VAD
1 +Ifo+ Carbo
6 primary
surgery
VA
10 1st line
6 2nd line (add D or
E+ C)
4 3rd line
83 primary
surgery
11 EE4A
13 DD4A
9 modif (upgrade EE to
DD, add C+Carbo)
7 primary surgery
28 VA 13 primary
surgery
SIOP protocols
since 1971
6 primary surgery
10 VA
6 VAD
10 VA
4 VAD
5 VA∗3
1 VA+ E+
Ifo+ cisplat
3 VA
11 VAD
1 VADC
4 VADCE
Duration preop CT 12 weeks (1–40) 80 days (47–89) 14.2 weeks (8–24)
Histology
Stage 1 25 (27%) 19 (40%) 63 (17%) 15 (54%) 11 (50%) 6 (32%)
Stage 2 26 (28%) 14 (30%) 215 (57%) 2 (7%) 11 (50%) 12 (63%)
Stage 3 28 (30%) 14 (30%) 73 (19%) 11 (39%) 0 6? 1 (5%)
No stage 14 (15%) 2 12 (7%) 0 0
Low risk With IR 16 (15%) ? 1 With IR 1 (5%)
Intermediate risk 67 (76%) 78 (83%) 78 (29%) 27 17 (77%) 8 (42%)
High risk
(Blastema only)
8 (9%) 0 17 (7%) 0 7 (10%) 5 (23%) 9 (47%) 8 (42%)
Diffuse
Anaplasia
10 (12%) 2 (2%) 16 (6%) 0 0 With above With above With above 2 (11%)
NR 37 Kidneys (39%) 17 Kidneys
(5.5%)
21 (30%) 18 (95%)
Postop CT 4 no postop CT (no
response to preop
CT)
18 VA
22 VAD
4 VA+ other drugs
EE4A
DD4A
2nd line in 87
(46%)
Stage 2
regimen
59 VAD
5 VA+ C
5 VA
1 V
10 VA
7 VAD
4 VAD+ Ifo+ Eto
1 died at preop phase
Radiotherapy 20 (22%) 11 (22%) 64 (34%) 4 (13%) 21 (30%) 5 (20%) 0 13 (65%) 2 (11%)
Relapse 27 (29%) 7 (14%) 54 (28%) (13%) (18%) 16 (23%) 1 (4.5%) 2 (10%) 6 (32%)
OS/EFS 80%/66.5% (4y) 89%/83% (5y) 84%/70%
(8y)
93%/85% (5y) 85%/80% 69% (6y) 75.6% (20y) 61% (3y) 85% (2y) 51.6%/29.2%
(5y) for S
80%/80%
(5y) for Me
ESRD At least 1 (1%) 7 (14%) 23 (12%) 4 (13%) 5 (7%) 8 (32%) 1 (5%) 2 (10%) 2 (11%)
CT, chemotherapy; V, vincristine; A, Actinomycin D; D, doxorubicin; C, cyclophosphamide; E, etoposide; Ifo, ifosfamide; carbo, carboplatin; cisplat, cisplatine; ESRD, end-stage renal disease; NR, nephro-
genic rests; S, synchronous; Me, metachronous.
B
IL
A
T
E
R
A
L
W
IL
M
S
T
U
M
O
U
R
9
https://w
w
w
.cam
bridge.org/core/term
s. https://doi.org/10.1017/erm
.2017.8
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core. U
niversity C
ollege London, on 01 A
ug 2017 at 10:41:28, subject to the C
am
bridge C
ore term
s of use, available at
TABLE 3.
SURGICAL MANAGEMENT OF BWT PATIENTS
AEIOP (Ref. 59) SFCE
(Ref. 64)
NWTS (Ref. 58) JPLT (Ref. 62) GPOH/SIOP9
(Ref. 65)
UKW2 (Ref. 60) Netherlands
(Ref. 56)
Egypt
(Ref. 63)
Durban
(Ref. 57)
Cape Town
(Ref. 61)
Total
Number of patients/
kidneys
93/176 49/94 188/376 31/56 28/ 70/114 25/ 22/ 20/37 19/ 545/
>853
Type of surgery NA
RN+NSS 31 (33%) 29 (59%) 53 (28%) 15 (48%) 32 (46%) 14 (56%) 13 (59%) 5 (26%) 192
RN+ Biopsy 12 (13%) 0 51 (27%) 0 0 0 3 (14%) 0 66
RN+Nothing With above 0 6 (3%) 0 10 (14%) 0 0 2 (11%) 18
Bilat NSS 35 (38%) 19 (39%) 35 (19%) 10 (32%) 10 (14%) 8 (32%) 3 (14%) 7 (37%) 127
Unil NSS+ Biopsy 0 0 10 (5%) 0 0 0 1 (4.5%) 0 11
NSS+ nothing 5 (5%) 0 3 (1%) 0 5 (7%) 0 0 1 (5%) 14
Bilat RN 1 (1%) 1 (2%) 6 (3%) 3 (10%) 1 (2%) 3 (12%) 1 (4.5%) 0 16
No surgery 3 (3%) 0 0 0 9 (13%) 0 1 (4.5%) 1 (5%) 14
Other procedures 1 (1%) bilat
biopsy
5 unknown
0 19 (10%) bilat
biopsy
5 (3%) unilat
biopsy
3 (10%)
unknown
1 (2%) bilat biopsy
3 (4%) bilat RN+ bench
surgery+
autotransplantation of 1
kidney
0 0 15 RN
22 NSS
3 (16%)
bilat
biopsy
40
others
15 RN
22 NSS
Surgical complications 1 chylous ascites
1 acute cerebral
ischaemia
1 urinary fistula
1 splenic injury
1 bowel
obstruction
NA 14 bowel
obstruction
1 extensive
haemorrhage
1 vascular injury
2 visceral injuries
2 urine leaks
1 urinary
obstruction
NA NA 3 haematuria
1 NSS converted to RN
2 bowel obstruction
1 intestinal perforation
1 diaphragmatic rupture
1 incisional hernia
NA 1 GI bleeding 2 bowel
obstruction
NA 40
RN, radical nephrectomy; NSS, nephron sparing surgery; GI, gastro-intestinal; NA, not assessed.
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frequent in bilateral WT operated on by NSS (Ref. 75).
Despite this high rate of stage III, and the fact that not
all stage III patients received radiotherapy, adminis-
tered at the discretion of the local physician (Refs 59,
64), the event-free and overall survival ranged from
61%/66.5% to 93%/85%, respectively (Table 2). In
a single retrospective review of bilateral WT cases,
the local recurrence rates after NSS did not prove to
be linked to the margin status despite the small
number of cases (Ref. 76). However, all patients with
positive margins were irradiated. The case for radio-
therapy in stage III patients is still a matter of debate
as in the French and Italian series, 35 and 43% of
stage III patients respectively did not receive radiother-
apy and were all alive at last follow-up (Ref. 64).
Unfavourable histology (blastemal type and diffuse
anaplasia) ranged from 2% (Ref. 64) to 53%
(Ref. 61) (median 21%) and correlated with outcome
(Table 2). Like for unilateral WT, histology remains a
major risk factor for outcome of bilateral WT, even
with adapted postoperative chemotherapy. A real dif-
ference in overall survival was also noticed between
synchronous and metachronous disease however only
one study separated the samples and sample size was
small (Table 2) (Ref. 61). Among the studies involving
only synchronous disease, the relapse rate ranged from
13 to 29% (Table 2), with around half being only local
relapse of whom half were treated by repeat NSS
(Refs 58, 77). No details were given on the survival
or recurrence rate depending on the presence or
absence of associated anomalies or syndromes
whether the bilateral disease was synchronous or
metachronous.
End Stage Renal Disease (ESRD) after bilateral WT
The major concern for bilateral WT patients after com-
plete remission of the disease is the evolution of their
renal function at long-term follow-up. ESRD was esti-
mated at 0.6% of unilateral nonsyndromic WT but
increased to 6.7% for patients with genito-urinary
anomalies, 36% for patients with WAGR and 74%
for DDS patients (Ref. 78). In cases of bilateral WT,
ESRD was 11.5% at a mean of 11.5 years follow-up
for nonsyndromic patients, 25% for patients with
genito-urinary anomalies, 90% for patients with
WAGR and 50% for DDS patients (Ref. 78).
Hypertension is another concerning risk at long-term
follow-up and has been estimated in a recent analysis
of GPOH patients at 66.7% of patients undergoing
total nephrectomy on one side versus 20% for patients
undergoing bilateral NSS. In a recent single institution
review of their bilateral WT operated on by NSS in
92.9% of cases, the authors showed a treated hyperten-
sion rate of 30.6% of the 36 living patients at a median
follow-up of 3.7 years (Ref. 79). An additional seven
patients presented nontreated persistent systolic or dia-
stolic blood pressure readings between the 90th and
95th percentile for their age group increasing the rate
of hypertension in the cohort to 50%. The renal
function assessed by Schwartz formula showed
36.1% of patients having an estimated glomerular fil-
tration rate of less than 90 ml/min/1.73 m2 but none
had <60 (Ref. 80).
Conclusions
Advances in understanding the molecular basis of WT
hold much promise for improving the management of
the rare but challenging scenario of bilateral disease.
Surgical treatment strives to preserve renal function
through NSS without compromising complete tumour
excision. This is generally facilitated by pre-operative
chemotherapy, which brings additional information
from assessment of histological response.
Interpretation of the completeness of tumour exci-
sion may be confounded by the difficulties in distin-
guishing NR from fully malignant WT. Here,
epigenetic changes may add to current knowledge
about the key genetic drivers (WT1 and IGF2 disrup-
tion) early in renal development and those occurring
as later events (MYCN, TP53 and CTNNB1 mutation).
Recent research has highlighted new pathways asso-
ciated with WT formation, including mutation of new
genes involved in renal development and the miRNA
processing pathway. The contribution of mutation in
these genes to bilateral disease and, separately, to risk
of renal failure, requires further assessment by epi-
demiological studies in combination with molecular
analysis. It is likely that these questions will be
answered in a relatively short time scale because of
large-scale collaborations and ever decreasing costs
of molecular analysis.
There remains a need for noninterventional methods
to predict histological subtype so that decisions about
intensification of pre-operative chemotherapy and
timing of surgery can be planned to maximise the pos-
sibility of NSS. Recent advances inMRI diffusion mea-
surements and in detecting circulating tumour DNA
may aid in assessment here (Ref. 55). Understanding
the full genetic spectrum of bilateral WT is important
for treatment planning and follow up to optimise the
overall survival of these children, many of whom are
expected to have constitutional mutations inWT predis-
position genes. These may contribute to their risk of
further tumours and of end stage renal failure as well
as increased tumour risk in their offspring. Optimum
management of bilateral WT requires an experienced
multi-disciplinary team with input from the point of
diagnosis of all the above specialist areas to achieve
the best outcome for each patient.
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